OBEZİTE TEDAVİSİ

Yazarlar

Filiz Özyiğit
https://orcid.org/0000-0002-0062-4281

Özet

Obezite tedavisi; sağlıklı beslenme, düzenli egzersiz, davranış terapisi ve farmakolojik yöntemlerin bütüncül bir şekilde uygulanmasını gerektiren multidisipliner bir süreçtir. Tek başına ilaç kullanımı kalıcı kilo kaybı sağlamak için yeterli ve sağlıklı kabul edilmemekte, ancak yaşam tarzı değişikliklerine yanıt vermeyen BKİ ≥30 kg/m² veya ek hastalığı olan BKİ 27–29,9 kg/m² bireylerde önerilmektedir. Tedavide Orlistat (yağ emilim inhibitörü), Liraglutid (GLP-1 analoğu), Fentermin, Dietilpropion ve çeşitli kombinasyon ilaçları (Fentermin/Topiramat, Naltrekson/Bupropion) onaylı seçenekler arasında yer alırken; Metformin, Pramlintid, Eksenatid ve Fluoksetin gibi ilaçlar endikasyon dışı kullanılabilmektedir. Geçmişte kullanılan fenfluramin, sibutramin ve rimonabant gibi ilaçlar ise ciddi kardiyovasküler, nörolojik veya psikiyatrik yan etkileri nedeniyle piyasadan çekilmiştir. İlaç seçiminde hastanın ek hastalıkları ve gebelik durumu gibi kontrendikasyonlar titizlikle değerlendirilmeli, olası ilaç etkileşimleri dikkate alınmalıdır. Tedavi başarısı, ilk 6 ayda toplam kilonun %5-10’unun kaybedilmesi ve hipertansiyon ile diyabet gibi obeziteye eşlik eden kronik hastalık risklerinin azalması ile ölçülür. Akılcı ilaç kullanımı ilkeleri doğrultusunda, güvenliliği ve etkinliği kanıtlanmış antiobezite ilaçlarının uzman hekim takibinde kullanılması şarttır.

Referanslar

Kayaalp, O. (2005). Rasyonel tedavi yonunden Tıbbi Farmakoloji. (11.baskı) Ankara: Hacettepe–Taş Yayınevi.

“Birinci Basamak Sağlık Kurumları İçin Obezite ve Diyabet Klinik Rehberi” Türkiye Halk Sağlığı Kurumu, Yayın No, 1070, Ankara ve 2017” ISBN: 978-975-590-644-7.

Adaş M, Mert M. Obezitede Medikal Tedavi.Okmeydanı Tıp Dergisi 30 (Ek sayı 1):50-55, 2014.

Knowler WC, Barret-Connor E, Fowler SE. Reduction in the incidence of type 2 diabetes with lifestyle inter¬vention or metformin. N Engl J Med 2002;346:393. http://dx.doi.org/10.1056/NEJMoa012512

Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) 2005;29:1153-1167.

Andres R, Muller DC, Sorkin JD. Long-term effects of change in body weight on all-cause mortality. A review. Ann Intern Med. 1993;119:737-743.

Altunkaynak BZ, Özbek E. Obezite: Nedenleri ve Tedavi Seçenekleri. Van Tıp Dergisi: 13 (4):138-142, 2006.

Altunkaynak, BZ, Özbek E. Obezite: Nedenleri ve Tedavi Seçenekleri Dicle Tıp Dergisi, 2007 Cilt: 34, Sayı: 2, (144-149).

Garvey WT, Mechanick JI, Brett EM, et al. Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association Of Clinical Endocrinologists And American College Of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care Of Patients With Obesity. Endocr Pract. 2016;22 Suppl3:1-203.

Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36:843–854.

Daniels GH, Hegedüs L, Marso SP, et al. LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. Diabetes Obes Metab. 2015;17:477–486.

Khera R, Murad MH, Chandar AK, et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016;315(22):2424-2434.

Kujawska-Łuczak M, Musialik K, Szulińska M, et al. The effect of orlistat versus metformin on body composition and insulin resistance in obese premenopausal women: 3-month randomized prospective open-label study. Arch Med Sci. 2017;13(4):725-731.

Sjostrom L, Rissanen A, Andersen T. et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167-172.

Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123-8.

Yanovski ZS, Yanovski AJ. Long-term drug treatment for obesity: A systematic and clinical review. JAMA 2014;311:74-86.

Johansson K, Sundstrom J, Neovius K, Rossner S, Neo¬vius M. Long term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Obesity Reviews 2010;11(11):777-791.

Zhou YH, Ma XQ, Wu C, et al. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. Plo¬SOne 2012;7(6):e39062. http://dx.doi.org/10.1371/journal.pone.0039062

Türkiye Endokrinoloji ve Metabolizma Derneği, (2018). Obezite Tanı ve Tedavi Kılavuzu ISBN: 978-605-4011-31-5. 80-6.

Tanakol R. Obezite Tedavisinde Orlistat. Turkish Journal of Endocrinology and Metabolism. Volume 7, Number 2, Page(s) 087-097, 2003.

Leblanc ES, O’Connor E, Whitlock EP, et al. Effec¬tiveness of primary care-relevant treatments for obe¬sity in adults: a systematic evidence review for thr U.S. Preventive Servies Task Force. Ann Intern Med 2011;155:434-447.

Weir MA, Beyea MM, Gomes T, et al. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med 2011;171:703-704. http://dx.doi.org/10.1001/archinternmed.2011.103

Padwal R, Li SK, Lau DC. Long-term pharnacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004;CD004094

Bray GA. Drug therapy of obesity. 2014; www.uptodate.com

Scott LJ. Liraglutide: a review of its use in the management of obesity. Drugs. 2015;75(8): 899-910.

Jeong KH, Yoo BK. The efficacy and safety of liraglutide. Int J Clin Pharm. 2011;33(5):740-9.

Ioannides-Demos LL, Proietto J, McNeil JJ. Pharma¬cotherapy for obesity. Drugs 2005;65(10):1391-1418. http://dx.doi.org/10.2165/00003495-200565100-00006

Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002;26(2):262-273 http://dx.doi.org/10.1038/sj.ijo.0801889

Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med. 2004;164(9):994-1003.

Cheung BM, Cheung TT, Samaranayake NR. Safety of antiobesity drugs. Ther Adv Drug Saf. 2013;4(4):171-81.

Türk Eczacılar Birliği (TEB). Sibutramin İçeren Ürünlerin Satışının Durdurulması ve Toplatılmasına Yönelik Geri Çekme Duyurusu. Sayı: 006064. Ankara: 2010.

Luc F. Obezite tedavisinde kullanılan çağdaş ilaçlar ve gelecek vaat eden ilaçlar. International textbook of obesity. Editör: Björntorp P. 451-469, Wiley&Sons Ltd., 2002.

Kang JG, Park CY. Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J. 2012;36(1):13-25.

Patel PN, Pathak R. Rimonabant: a novel selec-tive cannabinoid-1 receptor antagonist for tre-atment of obesity. Am J Health Syst Pharm 2007; 64: 481-9.

Van Gaal L, Pi-Sunyer X, Despres JP, et al. Efficacy and safety of rimonabant for improve-ment of multiple cardiometabolic risk factors in overweight/ obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008; 3: 229-40.

Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337(9):581-588.

Smith SR, Prosser WA, Donahue DJ, et al. APD356004 Study Group. Lorcaserin (APD356), a selective 5-HT(2C) agonist, redu-ces body weight in obese men and women. Obe-sity (Silver Spring) 2009; 17: 494-503.

O’Neil PM, Smith SR, Weissman NJ, et al. Randomi¬zed placebo controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM Study. Obesity (Silver Spring) 2012;20(7):1426-1436.

FDA Highlights of Prescribing Information: BELVIQ (lorcaserin hydrochloride) tablets, for oral use. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/

Smith SR, Weissman NJ, Anderson CM, et al; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight mana-gement. N Engl J Med 2010; 363: 245-56.

Fidler MC, Sanchez M, Raether B, et al. BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96: 3067-77.

Yanovski ZS, Yanovski AJ. Long-term drug treatment for obesity: A systematic and clinical review. JAMA 2014;311:74-86. http://dx.doi.org/10.1001/jama.2013.2813.

Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topira¬mate combination on weight and associated comorbi¬dities in overweight and obese adults (CONQOER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341-1352. http://dx.doi.org/10.1016/S0140-6736(11)60205-5

Allison GB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330-342. http://dx.doi.org/10.1038/oby.2011.330

http://www.fda.gov/downloads/Drugs/DrugSafety/Postmarket Drug Safety Information for Pati-ents and Providers/UCM312598.pdf.

Gaddde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and to¬lerability in overweight and obese women. Obes Res 2001;9:544-551. http://dx.doi.org/10.1038/oby.2001.71

Kennett GA, Clifton PG. New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol Biochem Behav 2010; 97: 63-83.

Khan A, Raza S, Khan Y, Aksoy T, Khan M, Weinberger Y, et al. Current updates in the medical management of obesity. Recent Pat Endocr Metab Immune Drug Discov. 2012;6(2):117-28.

Coulter AA, Rebello CJ, Greenway FL. Centrally acting agents for obesity: past, present, and future. Drugs. 2018;78(11):1113-32.

Bray GA, Ryan DH. Update on obesity pharmacotherapy. Ann N Y Acad Sci. 2014;1311: 1-13.

Satman İ, Salman S. Oral antidiyabetik ilaçlarla tedavi in: Yenigün M,Altuntaş. Y(eds):Her Yönüyle Diabetes Mellitus.Nobel Tıp kitabevi,İstanbul 2001;(19):933-949

Hollander P. Anti-diabetes and anti-obesity medications: effects on weight in people with diabetes. Diabetes Spectr. 2007;20(3):159-65.

Fontbonne A, Charles MA, Juhan-Vague I, et al. The ef¬fect of metformin on the metabolic abnormalities asso¬ciated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996;19:92-926.

Igel LI, Sinha A, Saunders KH, Apovian CM, Vojta D, Aronne LJ. Metformin: an old therapy that deserves a new indication for the treatment of obesity. Curr Atheroscler Rep. 2016;18(4):16. [Crossref] [PubMed]

de Jager J, Kooy A, Lehert P, Wulffelé MG, van der Kolk J, Bets D, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010;340:c2181. [Crossref] [PubMed] [PMC]

Erkekoğlu P, Baydar T, Şahin G. [Evaluation of obesity treatment approaches in geriatric group from atoxicological aspect-II: antiobesitic drugs]. Turkish Journal of Geriatrics. 2009;12(4):202-16.

Ratner RE, Dickey R, Fineman M, et al. Amylin rep¬lacement with pramlintide as an adjunct to insulin the¬rapy improves long-term glycaemic and weight cont¬rol in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med2004;21:1204-1212.

Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic cont-rol and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2011; 13: 169-80.

Dunican KC, Adams NM, Desilets AR. The role of pramlintide for weight loss. Ann Pharmacother. 2010;44(3):538-45.

Yen M, Ewald MB. Toxicity of weight loss agents. J Med Toxicol. 2012;8(2):145-52.

Ioannides -Demos LL, Proietto J, Tonkin AM, McNeil JJ. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf. 2006;29(4):277-302. [Crossref]

Wharton S, Serodio KJ. Next generation of weight management medications: implications for diabetes and CVD risk. Curr Cardiol Rep. 2015;17(5):35.

Krentz AJ, Fujioka K, Hompesch M. Anti-obesity pharmacotherapy: the intercontinental regulatory divide. Drugs. 2015;75(9):931-3.

Luc F. Obezite tedavisinde kullan lan çadailaçlar ve gelecek vaat eden ilaçlar. International textbook of obesity. Editör: Björntorp P. 451-469, Wiley&Sons Ltd., 2002

Afkhami-Ardekani M, Sedghi H. Effect of fluoxetine on weight reduction in obese patients. Indian J Clin Biochem. 2005;20(1):135-8.

Ricca V, Mannucci E, Mezzani B, Moretti S, Di Bernardo M, Bertelli M, et al. Fluoxetine and fluvoxamine combined with individual cognitive- behaviour therapy in binge eating disorder: a one-year follow-up study. Psychother Psychosom. 2001;70(6):298-306.

Melendez G, Serralde-Zúniga AE, Garay AGG, Rodríguez-Carmona Y, Galicia CS. Fluoxetine for adult overweight or obese people. Cochrane Database Syst Rev. 2015;5.

Appolinario JC, Bueno JR, Coutinho W. Psychotropic drugs in the treatment of obesity: what promise? CNS Drugs. 2004;18(10):629-51.

McElroy SL, Guerdjikova AI, Martens B, Keck PE Jr, Pope HG, Hudson JI. Role of antiepileptic drugs in the management of eating disorders. CNS Drugs. 2009;23(2):139-56.

Gadde KM, Kopping MF, Wagner HR, et al. Zonisami¬de for weight reduction in obese adults: a 1-year rando¬mized controlled trial. Arch Intern Med 2012;172:1557-1564.

McElroy SL, Guerdjikova AI, Martens B, Keck PE Jr, Pope HG, Hudson JI. Role of antiepileptic drugs in the management of eating disorders. CNS Drugs. 2009;23(2):139-56.

Questions and Answers about FDA’s Initiative Against Contaminated Weight Loss Pro-ductshttp://www.fda.gov/drugs/resourcesforyou/con sumers/questionsanswers/ucm136187. Htm.

Kopelman P, Bryson A, Hickling R, et al. Ceti-listat (ATL962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes 2007; 31: 494-9

Bryson A, De la Motte S, Dunk C. Reduction of dietary fat absorption by the novel gastrointesti-nal lipase inhibitor cetilistat in healthy volunte-ers. Br J Clin Pharmacol 2009; 67: 309-15.

Fehm HL, Smolnik R, Kern W, et al. The mela-nocortin melanocyte-stimulating hormo-ne/adrenocorticotropin (4-10) decreases body fat in humans. J Clin Endocrinol Metab 2001; 86: 1144-8.

Wynne K, Park AJ, Small CJ, et al. Subcutane-ous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005; 54: 2390-5.

Türkiye Endokrinoloji ve Metabolizma Derneği (2014) Obezite Tedavi Kılavuzu ve Yaşam Tarzı Önerileri, (Online), Ulaşılabilir: http://www.turkendokrin.org/files/pdf/Obezite.pdf (29 Temmuz2014).

Şenyüz CŞ, Reis R, Sipahi H. Gecmişten Gunumuze Obezite Tedavisinde Kullanılan İlaclar ve İstenmeyen Etkileri. J Lit Pharm Sci. 2019;8(1):61-75. DOI: 10.5336/pharmsci.2018-62684

Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. BMC Med. 2016;14(1):191.

Rosenfeld GC, Loose DS. (2017).Farmakoloji. (Hülagu BARIŞKANER, Çev. Ed.).İstanbul : İstanbul Tıp Kitapevleri.

Yayınlanan

11 Mayıs 2021

Lisans

Lisans